Terms: = Pancreatic cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Treatment
54 results:
1. Effect of cancer cachexia on first-line chemotherapy in patients with advanced pancreatic cancer: a claims database study in Japan.
Furuse J; Osugi F; Machii K; Niibe K; Endo T
Int J Clin Oncol; 2024 Apr; 29(4):456-463. PubMed ID: 38353906
[TBL] [Abstract] [Full Text] [Related]
2. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract] [Full Text] [Related]
3. FOLFIRINOX in pancreatic cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis.
Todaka A; Sasaki M; Ueno H; Goto T; Murohisa G; Mizuno N; Ozaka M; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Nanami S; Boku N
Anticancer Res; 2023 Sep; 43(9):4115-4123. PubMed ID: 37648306
[TBL] [Abstract] [Full Text] [Related]
4. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.
de Mestier L; Resche-Rigon M; Dromain C; Lamarca A; La Salvia A; de Baker L; Fehrenbach U; Pusceddu S; Colao A; Borbath I; de Haas R; Rinzivillo M; Zerbi A; Funicelli L; de Herder WW; Selberherr A; Wagner AD; Manoharan P; De Cima A; Lybaert W; Jann H; Prinzi N; Faggiano A; Annet L; Walenkamp A; Panzuto F; Pedicini V; Pitoni MG; Siebenhuener A; Mayerhoefer ME; Ruszniewski P; Vullierme MP
J Neuroendocrinol; 2023 Jun; 35(6):e13311. PubMed ID: 37345276
[TBL] [Abstract] [Full Text] [Related]
5. Risk Factors and Outcomes of Open Conversion During Minimally Invasive Major Hepatectomies: An International Multicenter Study on 3880 Procedures Comparing the Laparoscopic and Robotic Approaches.
Montalti R; Giglio MC; Wu AGR; Cipriani F; D'Silva M; Suhool A; Nghia PP; Kato Y; Lim C; Herman P; Coelho FF; Schmelzle M; Pratschke J; Aghayan DL; Liu Q; Marino MV; Belli A; Chiow AKH; Sucandy I; Ivanecz A; Di Benedetto F; Choi SH; Lee JH; Park JO; Prieto M; Guzman Y; Fondevila C; Efanov M; Rotellar F; Choi GH; Robles-Campos R; Wang X; Sutcliffe RP; Tang CN; Chong CC; D'Hondt M; Dalla Valle B; Ruzzenente A; Kingham TP; Scatton O; Liu R; Mejia A; Mishima K; Wakabayashi G; Lopez-Ben S; Pascual F; Cherqui D; Forchino F; Ferrero A; Ettorre GM; Levi Sandri GB; Sugioka A; Edwin B; Cheung TT; Long TCD; Abu Hilal M; Aldrighetti L; Fuks D; Han HS; Troisi RI; Goh BKP;
Ann Surg Oncol; 2023 Aug; 30(8):4783-4796. PubMed ID: 37202573
[TBL] [Abstract] [Full Text] [Related]
6. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2023 Jun; 58(6):575-585. PubMed ID: 37029223
[TBL] [Abstract] [Full Text] [Related]
7. FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors.
Lacombe C; Perrier M; Hentic O; Brixi H; De Rycke O; Cros J; Rebours V; Cadiot G; Ruszniewski P; de Mestier L
J Neuroendocrinol; 2023 Jan; 35(1):e13227. PubMed ID: 36599808
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy and safety of no-touch radiofrequency ablation for small hepatocellular carcinoma-a systematic review and single-arm meta-analysis.
Du F; Zhang L; Zhang Y; Fan H; Ren L
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102069. PubMed ID: 36513251
[TBL] [Abstract] [Full Text] [Related]
9. A case report of anterior mediastinal signet ring cell carcinoma.
Liu S; Zhao A; Mao M
Medicine (Baltimore); 2022 Dec; 101(48):e32202. PubMed ID: 36482538
[TBL] [Abstract] [Full Text] [Related]
10. pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD-3 study.
Nikšić M; Minicozzi P; Weir HK; Zimmerman H; Schymura MJ; Rees JR; Coleman MP; Allemani C;
Cancer Commun (Lond); 2023 Jan; 43(1):87-99. PubMed ID: 36353792
[TBL] [Abstract] [Full Text] [Related]
11. Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
Matsuoka H; Yamada T; Ohta R; Yoshida Y; Watanabe T; Takahashi M; Kosugi C; Fukazawa A; Kuramochi H; Matsuda A; Sonoda H; Yoshida H; Hasegawa S; Sakamoto K; Otsuka T; Hirata K; Koda K;
Int J Clin Oncol; 2022 Dec; 27(12):1859-1866. PubMed ID: 36201089
[TBL] [Abstract] [Full Text] [Related]
12. Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy.
Rosery V; Mika S; Schmid KW; Reis H; Stuschke M; Treckmann J; Markus P; Schumacher B; Albers D; Mende B; Lahner H; Wiesweg M; Schuler M; Siveke JT; Kasper S
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4315-4325. PubMed ID: 36071236
[TBL] [Abstract] [Full Text] [Related]
13. Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y;
Cancer Med; 2022 Oct; 11(20):3796-3808. PubMed ID: 35441477
[TBL] [Abstract] [Full Text] [Related]
14. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
Izquierdo-Sanchez L; Lamarca A; La Casta A; Buettner S; Utpatel K; Klümpen HJ; Adeva J; Vogel A; Lleo A; Fabris L; Ponz-Sarvise M; Brustia R; Cardinale V; Braconi C; Vidili G; Jamieson NB; Macias RI; Jonas JP; Marzioni M; Hołówko W; Folseraas T; Kupčinskas J; Sparchez Z; Krawczyk M; Krupa Ł; Scripcariu V; Grazi GL; Landa-Magdalena A; Ijzermans JN; Evert K; Erdmann JI; López-López F; Saborowski A; Scheiter A; Santos-Laso A; Carpino G; Andersen JB; Marin JJ; Alvaro D; Bujanda L; Forner A; Valle JW; Koerkamp BG; Banales JM
J Hepatol; 2022 May; 76(5):1109-1121. PubMed ID: 35167909
[TBL] [Abstract] [Full Text] [Related]
15. Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients.
Ogushi K; Chuma M; Numata K; Nozaki A; Moriya S; Uojima H; Kondo M; Morimoto M; Maeda S
Eur J Gastroenterol Hepatol; 2022 Jul; 34(7):774-781. PubMed ID: 35102114
[TBL] [Abstract] [Full Text] [Related]
16. [Comparative clinical efficacy analysis of pancreatoduodenectomy for distal bile duct and pancreatic head cancer: a report of 1 005 cases].
Wu PF; Zhang K; Lu ZP; Lin JZ; Chen JM; Xi CH; Wei JS; Guo F; Tu M; Jiang KR; Miao Y
Zhonghua Wai Ke Za Zhi; 2022 Feb; 60(2):128-133. PubMed ID: 35012271
[No Abstract] [Full Text] [Related]
17. First- and Second-Line Palliative Systemic treatment Outcomes in a Real-World Metastatic pancreatic cancer Cohort.
Pijnappel EN; Dijksterhuis WPM; van der Geest LG; de Vos-Geelen J; de Groot JWB; Homs MYV; Creemers GJ; Mohammad NH; Besselink MG; van Laarhoven HWM; Wilmink JW;
J Natl Compr Canc Netw; 2021 Aug; 20(5):443-450.e3. PubMed ID: 34450595
[TBL] [Abstract] [Full Text] [Related]
18. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
Chan DL; Bergsland EK; Chan JA; Gadgil R; Halfdanarson TR; Hornbacker K; Kelly V; Kunz PL; McGarrah PW; Raj NP; Reidy DL; Thawer A; Whitman J; Wu L; Becker C; Singh S
Oncologist; 2021 Nov; 26(11):950-955. PubMed ID: 34342086
[TBL] [Abstract] [Full Text] [Related]
19. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy.
Takeda T; Sasaki T; Suzumori C; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Int J Clin Oncol; 2021 Jul; 26(7):1293-1303. PubMed ID: 33791917
[TBL] [Abstract] [Full Text] [Related]
20. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Ueno M; Nakamori S; Sugimori K; Kanai M; Ikeda M; Ozaka M; Furukawa M; Okusaka T; Kawabe K; Furuse J; Komatsu Y; Ishii H; Sato A; Shimizu S; Chugh P; Tang R; Ioka T
Cancer Med; 2020 Dec; 9(24):9396-9408. PubMed ID: 33099898
[TBL] [Abstract] [Full Text] [Related]
[Next]
